Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Smoking by Pregnant Teens Trends Upward Again

January 1, 1999
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 1
Volume 8
Issue 1

HYATTSVILLE, Md-The number of teenagers who smoke while pregnant is on the rise again. Data from a new National Center for Health Statistics (NCHS) study show that smoking among pregnant women between the ages of 15 and 19 increased to 17.2% in 1995 and 1996 after declining for several years. Non-Hispanic whites, at 29%, had the highest rate of smoking among pregnant teenagers. The study found a significant decline overall in smoking by pregnant women, from almost 20% in 1990 to 14% in 1996.

HYATTSVILLE, Md—The number of teenagers who smoke while pregnant is on the rise again. Data from a new National Center for Health Statistics (NCHS) study show that smoking among pregnant women between the ages of 15 and 19 increased to 17.2% in 1995 and 1996 after declining for several years. Non-Hispanic whites, at 29%, had the highest rate of smoking among pregnant teenagers. The study found a significant decline overall in smoking by pregnant women, from almost 20% in 1990 to 14% in 1996.

Articles in this issue

Pittsburgh to Build New Cancer Center
NCI Initiates Two High-Priority Tobacco Research Programs
Breast Cancer Stamp Sells Well
Hospital Strategies To Prevent Invasive Aspergillosis Spread
‘Cancer Patients Should Be Assertive, Know Their Rights’
EBCTCG Update of Adjuvant Treatment for Early Breast Cancer
Younger Breast Cancer Patients at Increased Risk of Recurrence
Six Named to National Cancer Advisory Board
Trial Uses Vitamin A To Prevent Lung Cancer in Former Smokers
‘Medical School Curriculum Must Include Palliative Care’
Formation of Fibrin Clots Key to Angiogenesis
Some AIDS Experts Now Question ‘Hit Hard, Hit Early’ Strategy
M.D. Anderson Opens New Facility-‘Hospital for the Future’
Transplant Center Uses Cooperative Care Model
High School Seniors Smoking Less in 1998
Recent Videos
4 experts are featured in this series.
4 experts are featured in this series.
Two experts are featured in this series.
Two experts are featured in this series.
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
Advertisement

Results from the KOMET trial led to the approval of selumetinib in adults with NF1 symptomatic, inoperable plexiform neurofibromas.

FDA OKs Selumetinib in NF1 Symptomatic, Inoperable Plexiform Neurofibromas

Ariana Pelosci
November 19th 2025
Article

Results from the KOMET trial led to the approval of selumetinib in adults with NF1 symptomatic, inoperable plexiform neurofibromas.


Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

Michael Barish, PhD
November 17th 2025
Podcast

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.


The median PFS for patients with ovarian cancer who received niraparib maintenance in the real-world setting was 25.7 months.

Real-World Niraparib Efficacy Similar to Phase 3 Data in Ovarian Cancer

Tim Cortese
November 18th 2025
Article

The median PFS for patients with ovarian cancer who received niraparib maintenance in the real-world setting was 25.7 months.


Experts discussed supportive care and why it should be integrated into standard oncology care.

How Supportive Care Methods Can Improve Oncology Outcomes

Declan Walsh, MD;Denise B. Reynolds, RD;Adam Friedman, MD, FAAD;Daniel C. McFarland, DO;Michelle Fingeret, PhD;Christian J. Nelson, PhD;William S. Breitbart, MD
November 10th 2025
Podcast

Experts discussed supportive care and why it should be integrated into standard oncology care.


How Does NALIRIFOX Fit Into the Metastatic PDAC Treatment Paradigm?

How Does NALIRIFOX Fit Into the Metastatic PDAC Treatment Paradigm?

Ariana Pelosci
November 18th 2025
Article

Results from the NAPOLI 3 trial found NALIRIFOX is a viable option for first-line treatment of metastatic pancreatic adenocarcinoma.


Efficacy data from the phase 3 EPCORE FL-1 trial evaluating epcoritamab plus rituximab and lenalidomide in this population support the FDA’s decision.

FDA Approves Epcoritamab Combo in R/R Follicular Lymphoma

Roman Fabbricatore
November 18th 2025
Article

Efficacy data from the phase 3 EPCORE FL-1 trial evaluating epcoritamab plus rituximab and lenalidomide in this population support the FDA’s decision.

Related Content
Advertisement

Results from the KOMET trial led to the approval of selumetinib in adults with NF1 symptomatic, inoperable plexiform neurofibromas.

FDA OKs Selumetinib in NF1 Symptomatic, Inoperable Plexiform Neurofibromas

Ariana Pelosci
November 19th 2025
Article

Results from the KOMET trial led to the approval of selumetinib in adults with NF1 symptomatic, inoperable plexiform neurofibromas.


Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

Michael Barish, PhD
November 17th 2025
Podcast

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.


The median PFS for patients with ovarian cancer who received niraparib maintenance in the real-world setting was 25.7 months.

Real-World Niraparib Efficacy Similar to Phase 3 Data in Ovarian Cancer

Tim Cortese
November 18th 2025
Article

The median PFS for patients with ovarian cancer who received niraparib maintenance in the real-world setting was 25.7 months.


Experts discussed supportive care and why it should be integrated into standard oncology care.

How Supportive Care Methods Can Improve Oncology Outcomes

Declan Walsh, MD;Denise B. Reynolds, RD;Adam Friedman, MD, FAAD;Daniel C. McFarland, DO;Michelle Fingeret, PhD;Christian J. Nelson, PhD;William S. Breitbart, MD
November 10th 2025
Podcast

Experts discussed supportive care and why it should be integrated into standard oncology care.


How Does NALIRIFOX Fit Into the Metastatic PDAC Treatment Paradigm?

How Does NALIRIFOX Fit Into the Metastatic PDAC Treatment Paradigm?

Ariana Pelosci
November 18th 2025
Article

Results from the NAPOLI 3 trial found NALIRIFOX is a viable option for first-line treatment of metastatic pancreatic adenocarcinoma.


Efficacy data from the phase 3 EPCORE FL-1 trial evaluating epcoritamab plus rituximab and lenalidomide in this population support the FDA’s decision.

FDA Approves Epcoritamab Combo in R/R Follicular Lymphoma

Roman Fabbricatore
November 18th 2025
Article

Efficacy data from the phase 3 EPCORE FL-1 trial evaluating epcoritamab plus rituximab and lenalidomide in this population support the FDA’s decision.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.